ArticleJournal of clinical immunology2011

Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism.

Jaime Ramos-Cejudo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.